Pharmacoeconomic review report: Crisaborole ointment, 2% (Eucrisa) (Pfizer Canada Inc.) : indication : for topical treatment of mild-to-moderate atopic dermatitis in patients two years of age and older

Crisaborole 2% ointment (Eucrisa) is indicated for use in patients two years of age and older with mild-to-moderate atopic dermatitis (AD). Crisaborole is a topical ointment that is recommended for use twice daily, and should be applied as a thin layer to all affected areas of skin. The submitted pr...

Full description

Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH April 2019, 2019
Edition:Final with redactions
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:Crisaborole 2% ointment (Eucrisa) is indicated for use in patients two years of age and older with mild-to-moderate atopic dermatitis (AD). Crisaborole is a topical ointment that is recommended for use twice daily, and should be applied as a thin layer to all affected areas of skin. The submitted price is $138.00 per 60 g (or $2.300 per g). In the economic analyses, one 60 g tube was assumed to last for one month for adults and about five weeks (one month and 10 days) for children. The manufacturer submitted a cost-utility analysis comparing crisaborole to topical corticosteroids (TCS, betamethasone valerate 0.1%) or topical calcineurin inhibitors (TCIs, pimecrolimus 1% or tacrolimus [adults: 0.1%; children: 0.03%]). Two subgroups of interest were considered in the economic evaluation, defined by the patient's age (i.e., children two years to 17 years of age and adults 18 years of age and older). The primary analysis reflected the Health Canada indication, with scenario analyses conducted to reflect the submitted reimbursement indication (patients who have failed or are intolerant to a TCS treatment). The manufacturer's base-case model was conducted from the perspective of the Canadian publicly funded health care payer over a one-year time horizon for adults and a 15-year time horizon for children with monthly cycles. Discounting was not applied in the adult subgroup analysis but was applied in the children subgroup with future costs and benefits discounted at 1.5% per annum
Physical Description:1 PDF file (33 pages) illustrations